Health Trials

BAG3 Mutation Associated Dilated Cardiomyopathy

2

Review clinical trials related to BAG3 Mutation Associated Dilated Cardiomyopathy. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

An AAV Gene Therapy Trial of AFTX-201 in Adults With BAG3-Associated Dilated Cardiomyopathy (DCM)

This is a Phase 1/2, open-label, dose-exploration and dose-expansion, clinical trial evaluating the safety, tolerability, pharmacodynamics, and preliminary efficacy of a single intravenous infusion of AFTX-201 in adults with dilated cardiomyopathy caused by a BAG3 gene mutation

Participants needed: 22
Trial details
Phase: Phase 1, Phase 2Age: 18-55Biological sex: AllType: InterventionalSponsor: Affinia TherapeuticsUpdated: Jul 2, 2026Locations: 2
Eligibility criteria

Not listed

Read more
Status: Recruiting

ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy

This Phase 1/2 study is an open-label, dose finding and dose expansion study investigating the safety, tolerability, and efficacy of a single IV infusion of ALXN2350 in adult participants with BAG3 associated DCM.

Participants needed: 6
Trial details
Phase: Phase 1, Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Alexion Pharmaceuticals, Inc.Updated: Jun 15, 2026Locations: 10
Eligibility criteria

Pathogenic or likely pathogenic mutation in BAG3 [+3]

Presence of antibodies to AAV9 [+2]

Read more